Inhibikase Therapeutics (IKT) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free IKT Stock Alerts $1.90 +0.03 (+1.60%) (As of 03:59 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare moversmsn.com - April 22 at 11:13 AMInhibikase Therapeutics progresses in Parkinson's disease trialsinvesting.com - April 20 at 3:26 PMInhibikase Therapeutics (NYSE:IKT) Stock Price Down 1.4%americanbankingnews.com - April 19 at 2:40 AMInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programsglobenewswire.com - April 18 at 4:30 PMInhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick Factsmarkets.businessinsider.com - April 3 at 10:50 AMInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertensionglobenewswire.com - April 3 at 8:05 AMBuy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progressmarkets.businessinsider.com - April 3 at 1:15 AMInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 3:03 PMInhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectationsfinance.yahoo.com - April 2 at 3:03 PMQ4 2023 Inhibikase Therapeutics Inc Earnings Callfinance.yahoo.com - March 29 at 12:18 AMInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activityglobenewswire.com - March 27 at 4:15 PMInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disordersfinance.yahoo.com - March 7 at 9:46 AMInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disordersglobenewswire.com - March 7 at 8:30 AMInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disordersglobenewswire.com - March 7 at 8:30 AMBuy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s Pipelinemarkets.businessinsider.com - March 6 at 5:56 PMHC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - March 5 at 12:20 PMInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Proglobenewswire.com - February 28 at 4:05 PMInhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial Standingmarkets.businessinsider.com - February 21 at 11:55 PMHere's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Nowfinance.yahoo.com - February 15 at 1:54 PMInhibikase Therapeutics Inc (IKT)investing.com - February 10 at 1:10 PMInhibikase Discusses FDA Pathway for New Cancer Drugmsn.com - February 8 at 9:09 AMTenax Therapeutics, Equillium among healthcare moversmsn.com - February 7 at 1:07 PMInhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancersfinance.yahoo.com - February 7 at 1:07 PMNew Strong Buy Stocks for February 6thmsn.com - February 6 at 12:04 PMInhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinibfinance.yahoo.com - January 29 at 10:41 AMInhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?finance.yahoo.com - January 22 at 3:16 PMInhibikase Therapeutics appoints Lees-Rolfe as CFOmsn.com - January 17 at 8:39 AMInhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattarolifinance.yahoo.com - January 16 at 8:09 PMWhy Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarketmsn.com - January 5 at 9:59 AMInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programsfinance.yahoo.com - December 19 at 12:21 PMInhibikase Therapeutics Inc Ordinary Sharesmorningstar.com - December 15 at 6:22 PMInhibikase Therapeutics Gets FDA's Pre-NDA Meeting For IkT-001Promarkets.businessinsider.com - December 4 at 12:59 PMInhibikase Therapeutics GAAP EPS of -$0.86seekingalpha.com - November 14 at 9:04 PMEarnings Preview For Inhibikase Therapeuticsbenzinga.com - November 13 at 1:53 PMInhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023finance.yahoo.com - November 7 at 10:31 AMCorrecting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023finance.yahoo.com - November 7 at 10:31 AMInhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollmentfinance.yahoo.com - October 16 at 9:24 AMInhibikase Therapeutics Announces Orphan Drug Designation For Risvodetinibmarkets.businessinsider.com - October 4 at 11:39 PMPromising Developments and Financial Outlook for Inhibikase Therapeutics Prompt Buy Ratingmarkets.businessinsider.com - October 4 at 1:39 PMInhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophyfinance.yahoo.com - October 4 at 8:38 AMInhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activityfinance.yahoo.com - September 20 at 1:00 PMInhibikase Therapeutics Announces Development of Novel Formulation of risvodetinibfinance.yahoo.com - August 24 at 5:37 PMInhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinibfinance.yahoo.com - August 21 at 9:03 AMInhibikase Therapeutics (IKT) Gets a Hold from JonesTradingmarkets.businessinsider.com - August 18 at 6:28 PMInhibikase: 600 Mg IkT-001Pro Shows Bioequivalence To 400 Mg Dose Of Imatinib Mesylatemarkets.businessinsider.com - August 17 at 4:54 PMInhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Profinance.yahoo.com - August 17 at 4:54 PMHC Wainwright & Co. Reiterates Inhibikase Therapeutics (IKT) Buy Recommendationmsn.com - August 16 at 9:57 AMQ2 2023 Inhibikase Therapeutics Inc Earnings Callfinance.yahoo.com - August 16 at 4:56 AMInhibikase Therapeutics, Inc.: Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activityfinanznachrichten.de - August 15 at 7:16 AMInhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activityfinance.yahoo.com - August 14 at 9:15 PM Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. IKT Media Mentions By Week IKT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKT News Sentiment▼0.000.42▲Average Medical News Sentiment IKT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKT Articles This Week▼41▲IKT Articles Average Week Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNTI News COEP News SRNE News GENE News ONVO News BCDA News SRZN News APTO News CELZ News EVAX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:IKT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
